CSBio CSBio

X
[{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hua Medicine"},{"orgOrder":0,"company":"Sciwind","sponsor":"LYFE Capital","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Secures US$37 Million Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart, Lispro, and Glargine Presented at the American Diabetes Association\u2019s Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"Biosimilar","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Gan & Lee Pharmaceuticals"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia\u2019s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone\u00ae Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Gan & Lee Pharmaceuticals"},{"orgOrder":0,"company":"Eccogene","sponsor":"New Alliance Capital","pharmaFlowCategory":"D","amount":"$25.1 million","upfrontCash":"Undisclosed","newsHeadline":"Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Eccogene"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.

            Lead Product(s): Ecnoglutide

            Therapeutic Area: Endocrinology Product Name: XW004

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will support the development of Eccogene’s clinical-stage programs including Phase I trial of ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the Phase I trial of ECC4703, a THRb full agonist for NASH and lipid disorders.

            Lead Product(s): ECC5004

            Therapeutic Area: Endocrinology Product Name: ECC5004

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: New Alliance Capital

            Deal Size: $25.1 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes.The primary objective of this Phase 1 study is to investigate safety and tolerability of GZR18 in healthy volunteers.

            Lead Product(s): Glucagon-like Peptide-1 Analogue

            Therapeutic Area: Endocrinology Product Name: GZR18

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary technology BioChaperone®.

            Lead Product(s): Insulin Lispro

            Therapeutic Area: Endocrinology Product Name: BioChaperone Lispro

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Adocia

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).

            Lead Product(s): Insulin aspart

            Therapeutic Area: Endocrinology Product Name: GL-ASP

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sciwind Biosciences has completed a phase 1 clinical study of XW003, in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021.

            Lead Product(s): XW003

            Therapeutic Area: Endocrinology Product Name: XW003

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: LYFE Capital

            Deal Size: $37.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing February 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.

            Lead Product(s): Dorzagliatin,Empagliflozin

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY